Epacadostat plus pembrolizumab combination shows promise in advanced solid tumours
Headline results from the open-label phase I/II ECHO-202/KEYNOTE-037 trial assessing [...]
Headline results from the open-label phase I/II ECHO-202/KEYNOTE-037 trial assessing [...]
Immune-related adverse events (irAEs) are side effects that can develop [...]
These short videos explain the latest results from the following [...]
The immune checkpoint (PD-1) inhibitor, pembrolizumab, shows promise as a [...]
The results from the renal cell carcinoma (RCC) group of [...]
Immunotherapy has revolutionised the treatment of renal cell carcinoma (RCC). [...]
The following is a Practice Update interview with Dr Hans Hammers, Associate [...]
Data from a recent phase 1b study has shown that [...]
This article, published in Nature just before Christmas, gives a [...]
The US Food and Drug Administration (FDA) have granted Breakthrough [...]